Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy

Abstract Concurrent chemoradiation therapy (CRT) is the standard of care for patients with unresectable stage II/III lung cancer. However, systemic chemotherapy is required for patients who are ineligible for radical radiation therapy. There is little evidence to date for the safety and efficacy of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Taichi Matsubara, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Takashi Seto, Tatsuro Okamoto
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	chemoradiation therapy ICI locally non‐small cell lung cancer small cell lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/34e9b456402f4b74b9a51df3acabdd4c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:34e9b456402f4b74b9a51df3acabdd4c
record_format	dspace
spelling	oai:doaj.org-article:34e9b456402f4b74b9a51df3acabdd4c2021-12-02T02:34:56ZSuccessful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy1759-77141759-770610.1111/1759-7714.14200https://doaj.org/article/34e9b456402f4b74b9a51df3acabdd4c2021-12-01T00:00:00Zhttps://doi.org/10.1111/1759-7714.14200https://doaj.org/toc/1759-7706https://doaj.org/toc/1759-7714Abstract Concurrent chemoradiation therapy (CRT) is the standard of care for patients with unresectable stage II/III lung cancer. However, systemic chemotherapy is required for patients who are ineligible for radical radiation therapy. There is little evidence to date for the safety and efficacy of CRT administered after treatment with immune checkpoint inhibitors (ICIs). The cases reported here had inoperable stage III lung cancer (non‐small cell lung cancer and small cell lung cancer) and were ineligible for radical radiation therapy. They were administered ICIs plus chemotherapy and subsequently underwent late concurrent CRT. Because of the remarkable tumor shrinkage achieved by the ICIs plus chemotherapy, adverse events of CRT were tolerable. They were alive without tumor progression as of this report, over 1 year after CRT was terminated. CRT is administered with curative intent, while the intent of immunochemotherapy is palliative. Late concurrent CRT after immunochemotherapy is probably effective and tolerable. After treatment with systemic chemotherapy in patients judged ineligible for radical radiation therapy, radiation therapy should be reconsidered because of its importance once tumor shrinkage has been achieved.Taichi MatsubaraShinkichi TakamoriTakatoshi FujishitaRyo ToyozawaKensaku ItoMasafumi YamaguchiTakashi SetoTatsuro OkamotoWileyarticlechemoradiation therapyICIlocally non‐small cell lung cancersmall cell lung cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENThoracic Cancer, Vol 12, Iss 23, Pp 3286-3289 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chemoradiation therapy ICI locally non‐small cell lung cancer small cell lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	chemoradiation therapy ICI locally non‐small cell lung cancer small cell lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Taichi Matsubara Shinkichi Takamori Takatoshi Fujishita Ryo Toyozawa Kensaku Ito Masafumi Yamaguchi Takashi Seto Tatsuro Okamoto Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
description	Abstract Concurrent chemoradiation therapy (CRT) is the standard of care for patients with unresectable stage II/III lung cancer. However, systemic chemotherapy is required for patients who are ineligible for radical radiation therapy. There is little evidence to date for the safety and efficacy of CRT administered after treatment with immune checkpoint inhibitors (ICIs). The cases reported here had inoperable stage III lung cancer (non‐small cell lung cancer and small cell lung cancer) and were ineligible for radical radiation therapy. They were administered ICIs plus chemotherapy and subsequently underwent late concurrent CRT. Because of the remarkable tumor shrinkage achieved by the ICIs plus chemotherapy, adverse events of CRT were tolerable. They were alive without tumor progression as of this report, over 1 year after CRT was terminated. CRT is administered with curative intent, while the intent of immunochemotherapy is palliative. Late concurrent CRT after immunochemotherapy is probably effective and tolerable. After treatment with systemic chemotherapy in patients judged ineligible for radical radiation therapy, radiation therapy should be reconsidered because of its importance once tumor shrinkage has been achieved.
format	article
author	Taichi Matsubara Shinkichi Takamori Takatoshi Fujishita Ryo Toyozawa Kensaku Ito Masafumi Yamaguchi Takashi Seto Tatsuro Okamoto
author_facet	Taichi Matsubara Shinkichi Takamori Takatoshi Fujishita Ryo Toyozawa Kensaku Ito Masafumi Yamaguchi Takashi Seto Tatsuro Okamoto
author_sort	Taichi Matsubara
title	Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
title_short	Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
title_full	Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
title_fullStr	Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
title_full_unstemmed	Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
title_sort	successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/34e9b456402f4b74b9a51df3acabdd4c
work_keys_str_mv	AT taichimatsubara successfultreatmentoflocallyadvancedlungcancerusinglateconcurrentchemoradiationtherapyadministeredafterimmunecheckpointinhibitorplusplatinumchemotherapy AT shinkichitakamori successfultreatmentoflocallyadvancedlungcancerusinglateconcurrentchemoradiationtherapyadministeredafterimmunecheckpointinhibitorplusplatinumchemotherapy AT takatoshifujishita successfultreatmentoflocallyadvancedlungcancerusinglateconcurrentchemoradiationtherapyadministeredafterimmunecheckpointinhibitorplusplatinumchemotherapy AT ryotoyozawa successfultreatmentoflocallyadvancedlungcancerusinglateconcurrentchemoradiationtherapyadministeredafterimmunecheckpointinhibitorplusplatinumchemotherapy AT kensakuito successfultreatmentoflocallyadvancedlungcancerusinglateconcurrentchemoradiationtherapyadministeredafterimmunecheckpointinhibitorplusplatinumchemotherapy AT masafumiyamaguchi successfultreatmentoflocallyadvancedlungcancerusinglateconcurrentchemoradiationtherapyadministeredafterimmunecheckpointinhibitorplusplatinumchemotherapy AT takashiseto successfultreatmentoflocallyadvancedlungcancerusinglateconcurrentchemoradiationtherapyadministeredafterimmunecheckpointinhibitorplusplatinumchemotherapy AT tatsurookamoto successfultreatmentoflocallyadvancedlungcancerusinglateconcurrentchemoradiationtherapyadministeredafterimmunecheckpointinhibitorplusplatinumchemotherapy
_version_	1718402341273600000

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy

Ejemplares similares